CDH1 and prostate carcinoma: This heterogeneity of response of various prostate cancer cells to alterations in KLK3 expression may explain why a lower level of CDH1 in CTCs was only observed in one of four models, despite the consistent decrease in KLK3 across all models, in the present study.